细胞毒性T细胞
癌症研究
抗原
主要组织相容性复合体
癌细胞
间质细胞
癌症免疫疗法
白细胞介素21
T细胞
生物
免疫疗法
抗原提呈细胞
免疫学
癌症
CD8型
免疫系统
体外
生物化学
遗传学
作者
Lucia Poncette,Julia Bluhm,Thomas Blankenstein
标识
DOI:10.1016/j.coi.2021.09.005
摘要
The focus in cancer immunotherapy has mainly been on CD8 T cells, as they can directly recognize cancer cells. CD4 T cells have largely been neglected, because most cancers lack MHC II expression and cannot directly be recognized by CD4 T cells. Yet, tumor antigens can be captured and cross-presented by MHC II-expressing tumor stromal cells. Recent data suggest that CD4 T cells act as a swiss army knife against tumors. They can kill cancer cells, if they express MHC II, induce tumoricidal macrophages, induces cellular senescence of cancer cells, destroy the tumor vasculature through cytokine release and help CD8 T cells in the effector phase. We foresee a great future for CD4 T cells in the clinic, grafted with tumor antigen specificity by T cell receptor gene transfer, either alone or in combination with engineered CD8 T cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI